Redefining the Standard of Care: The PROGRESS Trial Challenges the "Wait and See" Approach to Moderate Aortic Stenosis on November 3, 2026 Posted by
Decoding the Immune Stalemate: A New Frontier in Treating Chronic Diabetic Ulcers on November 3, 2026 Posted by
NewYork-Presbyterian and Spear Forge Landmark Partnership to Revolutionize Outpatient Rehabilitation Access Across NYC and Westchester on November 3, 2026 Posted by
Beyond the Salt Shaker: Why Potassium is the Missing Link in Global Heart Health on November 3, 2026 Posted by
Navigating the Future of Nutrition: A Comprehensive Review of the 2022-2023 Healthy Living Landscape on November 3, 2026 Posted by
Redefining the Standard of Care: The PROGRESS Trial Challenges the "Wait and See" Approach to Moderate Aortic Stenosis on November 3, 2026 Posted by
Decoding the Immune Stalemate: A New Frontier in Treating Chronic Diabetic Ulcers on November 3, 2026 Posted by
NewYork-Presbyterian and Spear Forge Landmark Partnership to Revolutionize Outpatient Rehabilitation Access Across NYC and Westchester on November 3, 2026 Posted by
Posted in Cancer Recovery Breaking the Resistance Barrier: Researchers Develop CS18, a Novel "Master Switch" Inhibitor for Hard-to-Treat Cancers on October 1, 2026
Posted in Cardiovascular Recovery Preventive Cardiology Breakthrough: PCSK9 Inhibitor Evolocumab Shows Promise for High-Risk Diabetes Patients on August 7, 2026
Posted in Medical Innovations A New Frontier in Cardiology: FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor on July 17, 2026
Posted in Medical Innovations A New Era in Cardiology: FDA Greenlights Enlicitide, the First Oral PCSK9 Inhibitor on July 16, 2026
Posted in Digital Health Tools Roche Claims Breakthrough in Lung Cancer Treatment with Next-Generation KRAS Inhibitor on July 3, 2026
Posted in Digital Health Tools A New Frontier in Myelofibrosis: Eli Lilly’s Novel JAK2 Inhibitor Shows Promise in Early Trials on June 21, 2026
Posted in Medical Innovations Setback in the Quest for a Parkinson’s Breakthrough: Biogen and Denali’s LRRK2 Inhibitor Fails Mid-Stage Trial on May 24, 2026 rifanmuazin
Posted in Digital Health Tools A Stalled Frontier: The Clinical Failure of Biogen and Denali’s LRRK2 Inhibitor in Parkinson’s Disease on May 22, 2026 rifanmuazin
Posted in Cardiovascular Recovery A New Frontier in Hypertension: FDA Approves Baxdrostat as First-in-Class Aldosterone Synthase Inhibitor on May 19, 2026 rifanmuazin
Posted in Digital Health Tools A New Frontier in Oncology: FDA Approves Beqalzi as First-in-Class BCL-2 Inhibitor for Mantle Cell Lymphoma on May 15, 2026 rifanmuazin
